Newron Pharmaceuticals S.p.a.

Pharmacia & Upjohn S.p.a.

University System of Maryland

Luca Benatti

Patricia Salvati

Ruggero Fariello

Carlo Cattaneo

Florian Thaler

Carmela Speciale

Elena Barbanti

Orietta Veneroni

Robert Schwarcz

Emanuela Izzo

Roberto Maj

Claudia Besana

Monica Mosca

Etsuo Okuno

Jerome Breton

Fariello Ruggero

Roberto Pellicciari

Massimo Cini

Stefano Rossetti

Nevie Covini

Simona Magagnin

Salvati Patricia

Claudia c/o Newron Pharmaceuticals SpA Besana

Florian c/o Newron Pharmaceuticals SpA Thaler

New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists.

Methods for treatment of Parkinson's disease

The present invention is in the field of pharmacotherapy of cognitive deficits in learning and memory by administering an &#x3b1;-aminoamide, particularly safinamide. Examples of disturbances in cognition that can be treated with compounds of the invention are the ones associated with disorders such as autism, dyslexia, attention deficit hyperactivity disorder, schizophrenia, obsessive compulsive disorders, psychosis, bipolar disorders, depression, Tourette's syndrome, Mild Cognitive Impairment (MCI) and disorders of learning in children, adolescents and adults, Age Associated Memory Impairment, Age Associated Cognitive Decline, Alzheimer's Disease, Parkinson's Disease, Down's Syndrome, traumatic brain injury Huntington's Disease, Progressive Supranuclear Palsy (PSP), HIV, stroke, vascular diseases, Pick's or Creutzfeldt-Jacob diseases, multiple sclerosis (MS), other white matter disorders and drug-induced cognitive worsening.

Alpha-aminoamide derivatives useful in the treatment of cognitive disorders

There is disclosed a pharmaceutical composition comprising gabapentin or an analogue thereof (pregabalin or tiagabine) and an &#x3b1;-aminoamide and its analgesic use. A synergistic effect of the respective analgesic activities without concomitant increase of side effects was observed.

Pharmaceutical composition comprising gabapentin or an analogue thereof and an &#x3b1;-aminoamide and its analgesic use

Methods of using certain &#x3b1;-aminoamide derivatives in the treatment of RLS and addictive disorders, The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.

Alpha-aminoamide derivatives useful in the treatment of addictive disorders

The invention relates to the use of certain alpha-aminoamide derivatives in the treatment of RLS and addictive disorders. The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.

&#x3b1;-Aminoamide derivatives useful in the treatment of restless legs syndrome

Methods for treatment of parkinson's disease

Methods of using certain &#x3b1;-aminoamide derivatives to treat lower urinary tract disorders. The therapeutic agents of the invention are able to reduce or even stop the lower urinary tract disorders substantially without side effects.

Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders

Recombinant KAT enzyme and process for its preparation

Recombinant kynurenine-3-hydroxylase enzyme and process for its

Disclosed are isolated DNAs encoding a kynurenine aminotransferase selected from the group consisting of: (a) an isolated DNA sequence which encodes rat KAT; (b) an isolated DNA sequence which hybridizes to the isolated DNA sequence of (a) above and which encodes a KAT enzyme; and (c) an isolated DNA sequence differing from the isolated DNA sequences of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a KAT enzyme. Also disclosed are vectors and host cells containing the same; oligonucleotide probes for identifying kynurenine aminotransferase; and isolated and purified kynurenine aminotransferase.

Recombinant kat enzyme from rat

Growing community of inventors

Cologno Monzese, Italy

Luca Benatti